Bluelinea achieves a net recovery in its EBITDA in the first half of 2022 – 06/10/2022 at 18:11


(AOF) – Bluelinea, a major operator of the “Silver Economy” in France, has published its 2022 half-year results and its revenue for the third quarter of 2022. In the first half of 2022, the net result recovered significantly and became positive again : it goes from a loss of 1.70 million euros to 1.77 million euros. Ebitda follows the same course and goes from -1.21 million euros to 249,000 euros. Turnover increased by 1.60 million euros to 5.21 million euros.

The third quarter of 2022 shows continued good commercial momentum, with continued robust organic growth (+7%) and the effect of the integration of the former Securitas Téléassistance. In the end, the consolidated turnover for the third quarter amounted to 2.51 million euros against 1.75 million euros a year earlier, an increase of 43%.

Driven by the continued deployment of the Serenea offer, which equipped 428 establishments at the end of September 2022 compared to 252 at the end of September 2021, the B2B activity of the Establishments division increased by 29%. At the same time, the Senior & Home division, bringing together the B2C activity, which supports 56,870 subscribers at the end of September 2022 against 34,817 at the end of September 2021, shows growth of 55%.

In the first 9 months of the financial year, Bluelinea achieved a turnover of 7.73 million euros against 5.36 million euros at the end of September 2021, i.e. a growth of 44%. As indicated on the occasion of the publication of the 2021 annual results, Bluelinea confirms its ambition to achieve organic growth of around 15% and a positive EBITDA for the 2022 financial year.

On this occasion, Laurent Levasseur, Chairman of the Management Board of Bluelinea, declared: “We achieved a first half of 2022 in line with our annual objectives. By generating double-digit growth and strictly controlling our cost base, we have succeeded in generating a positive Ebitda. If we maintain an organic growth rate of around 15% between now and the end of the year, which is the case at the end of September, the Bluelinea company will be able to claim a Positive EBITDA from this year 2022.

If we can today project ourselves serenely towards the future, it is thanks to the support of our new majority shareholder, the Apicil Group, which, by guaranteeing the success of the capital increase carried out during the summer, has provided us with the means to repay our debts and finance our now profitable growth. ”


An inevitable race for new blockbusters

The patent for Merck’s star product, the cancer drug Keytruda, which accounts for more than 35% of its sales, expires in 2028. Despite the loss, since 2019, of the patents for its three star products (Avastin, Herceptine, Rituxan) Roche was able to renew its portfolio by bringing new molecules to market. However, the discovery and launch of new drugs are increasingly expensive. AstraZeneca spends about $6 billion a year on R&D in a pharmaceutical industry where the life of a patent only lasts ten to fifteen years. This leads laboratories to withdraw from certain activities. Thus J&J, Pfizer, GSK and, no doubt, Novartis soon prefer to refocus on specialty drugs and abandon any ancillary activity.


Source link -86